Abstract | The notch signalling pathway is involved in differentiation, proliferation, angiogenesis, vascular remodelling, and apoptosis. Deregulated expression of notch receptors, ligands, and targets is observed in many solid tumours, including prostate cancer. Hypoxia is a common feature of prostate tumours, leading to increased gene instability, reduced treatment response, and increased tumour aggressiveness. The notch signalling pathway is known to regulate vascular cell fate and is responsive to hypoxia-inducible factors. Evidence to date suggests similar, therapeutically exploitable, behaviour of notch-activated and hypoxic prostate cancer cells.
Introduction
The notch pathway is an evolutionarily conserved sig nalling system that regulates the proliferation, differ entiation, cellfate determination, and selfrenewal of stem and progenitor cells in both embryonic and adult organs.
1,2 It is increasingly recognized as a signal ling pathway with oncogenic and tumour suppressor properties.
3,4 Notch deregulation has been reported in a wide range of tumours and is emerging as a novel therapeutic target. 5 The notch pathway is critical for normal cell proliferation and differentiation in the pros tate. As a result, deregulation of this pathway has been proposed to facilitate prostatic tumorigenesis 6 and pos sibly influence the outcomes associated with anticancer hormonal treatments. 7 Hypoxia is a common feature of prostate tumours and has been associated with disease progression and treatment resistance. 8 Many oxygenresponsive genes are regulated by the hypoxiainducible factor 1 (HIF1) complex. HIF1α overexpression, as evidenced by increased immunostaining, has been reported in a variety of human cancers (including prostate cancer) and their metastases.
9,10 Recent evidence suggests that HIF1 is recruited to notchresponsive promoters under hypoxic conditions to activate transcriptional targets. 11 In this Review, we evaluate the potential involvement of hypoxia in the deregulated expression of notch receptors, ligands, and targets in prostate cancer cells and consider the likely involvement of hypoxia and notch signalling in disease progression, treatment resistance, and the i dentification of novel therapeutic targets for prostate cancer.
Notch signalling in prostate
The human notch pathway is composed of ligands (jagged1, jagged2, and δlike proteins 1, 3, and 4) and receptors (notch 1-4). Ligand-receptor inter actions induce cleavage of the notch receptors, releasing the notch intracellular domain (NICD). The NICD trans locates to the nucleus and binds a transcriptional repres sor called recombining binding protein suppressor of hairless (RBPJ) converting it into a gene activator that induces the expression of downstream target genes, such as several helix-loop-helix transcription factors named transcription factor hes1 and hairy/enhancer ofsplit related with YRPW motif protein 1 (also known as hey1; Figure 1 ).
Notch receptors
Expression of the notch pathway family memberswhich exhibit tumourspecific and metastaticspecific patterns-has been measured in prostate cancer cells in vitro, in the transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model, and in patient tumour specimens. Of the four notch receptors, the expression of notch 1 has been studied the most. In one study, notch 1 transcript levels were significantly higher in prostate cancer LNCaP cells than in normal prostate PNT2 cells.
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In situ hybridization of tissue specimens from TRAMP mice showed that, although notch 1 was undetectable or expressed at very low levels in normal mature prostate tissue, hybridization signals were strong in malignant cells. 13 In another study, the percentage of notch1 positive cells was significantly greater in primary pros tate tumours than in adjacent benign tissue, and was slightly greater (approaching statistical significance) in bone metastatic cancer compared with primary prostate cancer.
14 Despite elevated notch 1 expression, notch 1 signal transduction could be diminished in prostate cancer. Indeed, immunostaining of the cleaved recep tor and its downstream effector hey1 were significantly reduced in adenocarcinoma foci when compared with benign tissues in a series of prostate sections from 16 patients with prostate carcinoma. 15 Although the mechanistic basis for loss of cleaved notch 1 remains to be elucidated, notch 1 cleavage has been shown to cor relate with loss of phosphatase and tensin homolog gene (PTEN) expression 15 and with calcium/calmodulin dependent kinase II overexpression. 16 Nonetheless, HES1 gene expression levels were higher in the metastatic PC3 cell line and in the strongly metastatic PC3derived PC3M cell line than in the LNCaP metastatic cell line.
Notch 2, notch 3, and notch 4 have been less exten sively studied than notch 1. In one study, notch 2 mRNA levels were described as elevated in three prostate cancer cell lines (LNCaP, PC3, and PC3M) relative to normal prostate cells (PNT2), whereas expression of notch 3 and notch 4 was not detected in any of the cell lines.
12 Strong expression of the notch 2 receptor has also been reported in gliomas, 17 breast cancers, 18 and colorectal cancers.
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In breast cancers, high notch 1 levels have been associ ated with poor prognosis, whereas increased notch 2 levels have correlated with greater probability of sur vival. 20 Increased expression of the notch 3 and notch 4 receptors has been less commonly reported in cancers, but levels of these proteins seem to be elevated in glio blastomas, 21 sali vary adenoid cystic carcinomas, 22 breast cancers, 23, 24 cervical cancers, 25 and ovarian cancers. 26, 27 The mechanistic significance of the expression of each notch r eceptor in tumours remains to be elucidated.
Notch ligands
Expression of the notch ligands jagged1, jagged2, and δlike protein 1 (also known as DLL1) has been reported in LnCaP, PC3, and PC3M metastatic pros tate cancer cells. 12 DLL1 gene expression levels were higher in androgen sensitive LNCaP cells than in androgenindependent PC3 and PC3M cells, suggest ing that DLL1 might be associated with the androgen response. 12 The expression of jagged1 was increased in all three cell lines relative to normal prostate cells, but jagged2 expression did not vary significantly among the cell lines. 12 The notch ligand protein jagged1 was significantly overexpressed in metastatic prostate cancer compared with localized prostate cancer or benign pros tatic tissues (according to immunohistochemical analysis of human tumour samples from 154 men). Furthermore, high jagged1 expression in a subset of clinically local ized tumours was significantly associated with disease recurrence. 28 In clinical specimens, the notch signal ling cascade was identified as one of the cellular path ways for which gene enrichment might distinguish highgrade (Gleason grade 8 [4 + 4]) from lowgrade (Gleason grade 6 [3 + 3]) pathologically localized pros tate cancer, 29 and expression of this pathway might be more pronounced in patients with a high BMI. 30 Evidence to date suggests dominant roles for notch 1 and jagged1 in the development of prostate cancer. Similarly, elevated expression of either protein has been associated with poor prognosis in patients with breast cancer. [31] [32] [33] The underlying mechanisms behind this genetic dominance remain to be elucidated, but could result from mutations in the notch 1 NICD 34 or Fbox/ WD repeatcontaining protein 7 (FBXW7). 35 Differential expression of FBXW7 isoforms has been shown to cor relate with advanced pathological stage and clinical recurrence of prostate cancer. 36 This genetic dominance might, alternatively, be the result of increased activa tion of the Wnt/βcatenin signalling pathway, which has also been observed in prostate cancer. 37, 38 Both Wnt/β catenin and notch 1 signalling pathways are thought to have an important role in cell proliferation and survival. Bcatenin was shown to regulate the level and transcrip tional activity of notch 1 in mouse embryonic fibroblasts and human embryonic kidney 293 cells. 39 Preferential expression of notch 1 and βcatenin were associated with a stemcelllike phenotype in prostate cancer cells. 40 Finally, numb, an important cell fate determinant protein, has been highlighted as a negative regulator of notch signalling in cancer. 41, 42 Loss of numb expres sion has been shown to increase notch activity in lung cancer cells 43 and, in one study, was described in >50% of primary breast tumours. 44 The expression pattern of numb in prostate cancer, although yet to be reported, might provide some insight into the regulation of notch in prostate cancer development.
Notch signalling and hypoxia
A number of studies have reported crosstalk between notch and hypoxia signalling pathways. 45 Notch activity has been associated with expression of vascular endo thelial growth factor (VEGF) 46 and HIF1α 47 -two wellrecognized markers of tumour hypoxia. HIF1 is recruited to notchresponsive promoters under hypoxic conditions to activate transcriptional targets and potentially regulate cell differentiation.
11 It can inter act with the NICD to augment the notch downstream response. This crosstalk between notch and hypoxia signalling seems to be mediated by the activation of factor inhibiting HIF1 (FIH1). 48 The accumulation of HIF1α and HIF2α in breast cancer cells with hypoxia is thought to potentiate stabilization of the NICD of the notch 1 receptor 46, 49, 50 and induce notch signalling via the NICD of the notch 3 receptor. 50 Low oxygen levels (1%) also increases the expression of HEY1 and HES1 notch target genes, as well as NOTCH3, JAG1, and JAG2 genes in breast cancer cell lines, indicating that hypoxia could regulate notch signalling in breast cancer. 50 In these cells, notch signalling mediates epithelial to mesen chymal transition (EMT), cell migration, cell invasion, and cell tube formation under hypoxic conditions. Activation of JAG2 by hypoxia might enhance the meta static potential of breast cancer cells. 51 Reduced oxygen concentrations were also associated with increased acti vation of notch 1 in lung tumours, 52 ,53 melanoma, 54 and malignant mesothelioma. 55 Key points ■ Evidence to date suggests dominant roles for notch 1 and the notch 1 ligand jagged-1 in the development of prostate cancer ■ A number of parallels exist between the cellular behaviour of notch-activated and hypoxic prostate cancer cells ■ The antitumour potential of novel strategies that target hypoxia-inducible factor 1 (HIF-1) seems closely related to their ability to inhibit notch signalling and target the cancer stem cell population ■ Notch and hypoxia signalling pathways might compete to control androgen-dependent molecular responses
Although most of the research to date has concentrated on other cancer types, a relationship between notch sig nalling and hypoxia in prostate cancer is possible. In one study, prostate cancer cell lines exposed to low oxygen concentrations assumed a neurallike pheno type, accom panied by upregulation of three neuro endocrine markers and a significant decrease in levels of notch 1, notch 2, DLL1, DLL4, hes1, and hey2 mRNA and protein expres sion. However, activation of neuroendocrine differentia tion, which has been associated with poor prognosis and limited response to androgen deprivation therapy (ADT), was only seen in the a ndrogensensitive LnCaP cell line. 56 A number of parallels exist between the cellular behav iour of notchactivated and hypoxic cells, suggesting that the notch pathway might be responsive to hypoxia in prostate cancer cells. Downregulation of jagged1 in prostate cancer cells has been associated with cell growth inhibition and S phase cell cycle arrest. As a result, jagged1 has been proposed as a potential therapeutic target for the treatment of prostate cancer. 57 Hypoxia is known to reduce proliferation rates and trigger S phase arrest in p53mutant cells, 58 suggesting a potential role of jagged1 in the hypoxic response. p53mediated upregu lation of notch 1 expression in human cancer cell lines, including PC3 and LNCaP, has been shown to contribute towards cell fate determination after genotoxic stress. 59 Similarly, transfection of prostate cancer cell lines LNCaP, DU145, and PC3 with a constitutively active form of notch 1 has been shown to result in reduced prolifer ation rates.
13 PTEN has also been reported to inhibit the phos phoinositide 3kinase (PI3K) pathway, participating in a reduction in HIF1α cytoplasmic levels. Loss of PTEN has been associated with an elevated HIF1α activation response to hypoxia 60 and proposed as a critical event in the development of resistance to notch inhibition in Tcell lymphoma. 61 Cancer stem cells Over the past decade, a substantial amount of evidence has been published that highlights the importance of interplay between hypoxia and the notch pathways in tumour progression and treatment resistance resulting from the maintenance of the stem cell population. [62] [63] [64] In breast cancer cells, the interaction of p66Shc with notch 3 following hypoxic exposure leads to increased cell survival and stem cell selfrenewal via expression of the hypoxiasurvival gene carbonic anhydrase IX and the notch ligand jagged1. 23 Inhibition of notch 1 signalling in adenocarcinoma of the lung has been shown to reduce hypoxic cell survival. 53 In one study, HIF2α maintained a stem cell phenotype in glioblastomas. 65 Consequently, the antitumour potential of novel antiHIF strategies seems to be closely related to their ability to inhibit notch signalling and target cancer stem cell populations. [66] [67] [68] [69] Although this interplay has not yet been established in prostate cancer, existing evidence strongly supports this link. A number of studies have highlighted a link between notch signalling and the prostate stem cell popu lation. Gene expression analysis indicates a higher level of notchsignallingpathway activity in prostate stem cells than in parental cell lines.
6,70 Treatment of DU145 pros tate cancer cells with the hepatocyte growth factor leads to the induction of a stemcelllike phenotype associated with activation of notch signalling. 71 Increases in notch 1 and hey1 expression are thought to prevent the differ entiation of prostate epithelial cells. 72 Immunochemistry for EMT markers in formalinfixed, paraffinembedded tissue from surgically resected prostate cancer speci mens has outlined a key role for notch 1 expression in EMT and the metastatic process of prostate cancer. 14 In human metastatic prostate cancer cells, loss of miR 8/200 has been associated with inhibition of jagged1 and proliferative activity. 73 Docetaxel resistance in prostate cancer cells has been attributed to a notchoverexpressing s ubpopulation of cells with stemlike properties. 74 Similarly, a few studies have highlighted a link between hypoxia signalling and the prostate stem cell population. Profiling experiments have revealed signifi cant overlap between hypoxic cells in primary prostate tumours and human embryonic stem cell gene signatures. Immunostaining of these patient specimens revealed that 69% of the primary prostate tumour cells that were posi tive for the stem cell marker NANOG were also HIF1α positive. 75 Exposure to hypoxic conditions has also been shown to enrich the CD44/CD41positive cell population in PC3 cells 76 and induce pluripotency and EMT in meta static prostate cancer cells. 77 Thus, reports of hypoxia induced notch signalling in prostate cancer stem cells are expected to emerge soon. Androgen deprivation conditions A fundamental challenge in prostate cancer research involves understanding the transition of cancer cells from androgen dependence to androgen independence. Hypoxia is thought to participate in androgen resis tance under conditions of androgen deprivation via the induction of androgen hypersensitivity 78 and the ampli fication of androgen receptor (AR) activity. 79 In the presence of antiandrogens, receptor inhibition is likely to involve recruitment of corepressor proteins, which interact with an antagonistoccupied receptor, but inhibit receptor dependent transcription. Hey1 has been shown to compete with AF1 to repress t ranscription from ARdependent promoters. 80 Although, in one study, amplification of the hey containing region of chromosome 8 was reported in the majority of individuals with androgenindependent prostate cancer, 81 hey protein expression was reduced in prostate cancer foci when compared with adja cent benign tissue. 15 Further investigation revealed that hey1 localization is altered in cancer and hey1 is excluded from the nucleus of prostate cancer cells. 82 Researchers have proposed that sequestration of hey1 in the cytoplasm of prostate cancer cells prevents repres sion of ARdependent genes and has a role in the aber rant hormo nal responses observed in prostate cancer, u ltimately participating in androgen resistance. 82 ADT causes atrophy of the prostatic epithelium as a result of apoptosis and reduced cell proliferation. A decrease in mitotic index, low Ki67, and down regulated VEGF are all associated with a favourable effect of antiandrogen treatment. [83] [84] [85] Recent evidence suggests a relationship between the notchresponsive, androgenresponsive, and hypoxiaresponsive pathways. HIF1α is recruited to notchresponsive promoters under hypoxic conditions to activate transcriptional targets 11 and crosstalk between AR and HIF1α has been identi fied in prostate cancer cells. 86 PSA expression is induced by both hypoxia and dihydrotestosterone via a hypoxia responsive region in the human PSA promoter, suggest ing that HIF1α competes with hey1 under hypoxic conditions to conserve survivalpromoting gene expres sion (Figure 2 ). Further research is needed to confirm the role of the notch pathway in conditions of hypoxia and in determining androgendependent cell fate.
Treatment resistance
The notch pathway might participate in the develop ment of resistance to chemotherapy and radiotherapy in hypoxic cells. Given that AR activity has been associ ated with cytotoxicity, 87 it seems reasonable to assume that the AR might participate in the chemoresponse of hypoxic cells. Recent studies have reported that response to taxanes, the only chemotherapeutic agent proven to be efficacious in prolonging overall survival in patients with prostate cancer, is maximized under conditions of AR activity. 88 On the other hand, HIF1α over expression in hypoxic cells has been shown to reduce the effec tiveness of microtubuledisrupting agents in a drug dosedependent manner in human ovarian cell lines. 89 Similarly, we have reported sensitivity of hypoxic pros tate cancer cells to docetaxel and a novel microtubule disrupting agent pyrrolo1,5benzoxazepine 15 (PBOX 15). 90, 91 Understanding the relationship between these three pathways could, therefore, uncover key targets for optimizing treatment response.
The notch pathway interacts with the PI3K and NFkB pathways, both of which are switched on by hypoxia and ionizing radiation (and possibly also by chemo therapeutic agents). These stressresponsive signal ling pathways influence the cellular concentration and interaction affinity of HIF1α, suggesting a cooperative effort of hypoxia and radiation on therapeutic resistance. Activation of RAS, RAF1, mitogenactivating protein kinase (MAPK), p38, and PI3K pathways has been associated with radioresistance 92 and could account for hypoxiainduced survival advantages via direct inhibi tion of apoptosis or enhanced HIF1α activity. 93, 94 Breast cancer, chronic lymphoid leukaemia, and myeloma cells with aberrant notch 1 signalling become chemo resistant upon inhibition of the p53 pathway by the mTOR dependent PI3K/AKT/PKB pathway. 95, 96 Silencing of notch 1 has been shown to promote docetaxelinduced cell growth inhibition, apoptosis, and cell cycle arrest in PC3 cells, 97 whereas expression of the notch 2 homo logue protein has been associated with radiosensitivity in patients with locally advanced adenocarcinoma of the rectum. 98 No studies have identified a role for notch in the radiation response of prostate cancer cells. Nonetheless, proliferative activity and neuroendocrine differentia tion have both been associated with radiation therapy failure in patients with prostate cancer, 99 suggesting that the notch pathway could potentially provide a prognos tic signature. High DLL4 expression has been linked with favourable outcome to radiotherapy in patients with locally advanced squamous cell head and neck cancers. 100 Inhibition of notch has been shown to enhance the sensitivity of cancer stem cells to radiation in vitro in a number of cancers, including naso pharyngeal carci noma, 101 colorectal carcinoma, 102,103 pancreatic cancer, 104 and glioma. 105 Given its ability to control survival of cancer stem cells, notch targeting could help to overcome resistance to radiation therapy, as the number of cancer stem cells is a determinant of tumour control. 106 
Tumour vasculature
The notch signalling pathway is essential to the regu lation of blood vessel structure 107 and defects in this pathway cause inherited vascular and cardiovascular diseases. 108 Tumour blood vessels are thinwalled, with abnormal branching and blind endings. 109 Their endo thelial lining is incomplete, showing fenestrations and loss of intercellular junctions. 110 The basement mem brane is also often incomplete or absent, and associated with a paucity of smooth muscle cells and pericytes. 111, 112 These features suggest that cancer is a vascular disease, associated with deregulation of the notch pathway. The role of the notch pathway in the regulation of tumour angiogenesis has been reviewed previously. 47 
REVIEWS
The blood vessel network is central to tumour biology and an important structure to consider during the develop ment of anticancer treatments. Evidence has connected tumour aggressiveness and poor patient sur vival with density of microvessels, which are structurally and functionally defective in many human malignancies, including prostate cancer. 113, 114 Microvessel density has also been proposed as a molecular marker for identifying highgrade prostatic intraepithelial neoplasia (HGPIN) lesions that are more likely to progress 115 and improving the prognostic stratification of patients with moder ately differentiated prostatic adenocarcinoma after radical prostatectomy. 116, 117 Although not yet demonstrated, notch signalling is also likely to be involved in the a ngiogenesis of prostate tumours.
Perfusion is relatively ineffective (owing to arterio venous shunts) and ≤30% of the total blood flow in tumours can bypass the exchange system of capillar ies. 118, 119 Solid (mechanical) stress generated by prolifer ating tumour cells also compresses vessels in tumours. 120 As a result, the tumour microcirculation suffers from impaired, multidirectional, and intermittent blood flow, impaired interstitial fluid drainage, increased interstitial fluid pressure, and increased vascular permeability. 121 In adult rat vascular smooth muscle cells, mechanical stress has been shown to result in reduced proliferation rate and enhanced apoptosis induction via reduced expression of notch 3, jagged1, and notch target gene products. 122, 123 This mechanism could be responsible for several vascu lar diseases, including arthrosclerosis. Reversal of this effect occurred when cells were transduced with a notch 3 expressing vector. 122, 123 Circulation defects within tumour blood vessels might trigger a response similar to that of mechanical injury in normal vessels.
Because tumour blood vessels provide unique and specific markers, such as VEGF, many targeted cancer therapies have been developed to deprive cancer cells of nutrients and prevent tumour expansion by vascu lar destruction. Destruction and remodelling of the tumour vasculature have been observed by interfering with VEGF signalling. 124 Despite the fact that vascular destruction is effective at inducing tumour necrosis, the effect of antiangiogenic therapies seems to be transient. Loss of endothelial cells is not necessarily accompanied by simultaneous loss of pericytes and surrounding base ment membrane, which together can result in regrowth of tumour vessels. 125 Upon completion of antiangio genic therapy, the tumour vasculature rapidly regains its p retreatment state. 126 VEGF stimulates the notch ligand DLL4 to act as a negativefeedback regulator that delays vascular sprout ing and branching. 127 AntiDLL4s have been shown to inhibit tumour growth in vivo by triggering excessive, but nonfunctional, angiogenesis-suggesting potential roles as novel anticancer agents. 128 In a murine model, DLL4 blockade resulted in the formation of a dense and disorganized capillary network that was unable to supply limb muscles with adequate perfusion (femoral artery ligation). 129 However, the blockade of notch pathway via treatment with a low or intermediate dose of a soluble DLL4 fusion protein (DLL4Fc) prompted the growth and maturation of new vessels in a hind limb isch aemia mouse model, enabling enhanced perfusion and increased vascu lar proliferation. 130 By contrast, PC3 cells transplanted with a retroviral vector to induce DLL4 over expression displayed decreased vessel density and vessel number (yet exhibited larger vessels with larger lumina) and decreased numbers of apoptotic cells, resulting in better perfusion and decreased hypoxia in vivo. 131 These contradictory data could indicate that DLL4 has a role in the development of tumour vasculature, but its effect depends on the amount of protein present in the cell.
The jagged2 ligand is upregulated in hypoxic breast cancer cells, and its expression significantly correlates with genes involved in the angiogenic process. 51 Depletion of jagged2 from the epithelial T47D breast cancer cell line has been shown to result in a reduction of MS1 cell tube formation. 50 Other research suggests that hypoxic conditions lead to the induction of the notch ligand DLL4 and the notch target genes hey1 and hey2 in endothelial progenitor cells. Hey factors are also capable of repressing HIF1αinduced gene expression in endothelial progeni tor cells, suggesting a negative feedback loop to prevent excessive hypoxic gene induction. 132 Induction of the notch ligand jagged1 by growth factors (via MAPK) in head and neck squamous cell carcinoma cells triggers notch activation in neighboring endothelia l cells and promotes capillarylike sprout formation. 133 A combination of intermittent hypoxia and ionizing radiation results in HIF1α overexpression, enhanced endothelial cell migration and tube formation capa city, and increased radioresistance. 134 The expression of DLL4 in endothelial cells is synergistically upregulated by VEGF and basic fibroblast growth factor, as well as by HIF1α under hypoxic conditions. 135 Downregulation of hey1 in response to DLL4targeted RNA inter ference leads to inhibition of endothelial cell prolifer ation, migration, and network formation. Thus, hey over expression resulting from hypoxiainduced DLL4 u pregulation might contribute to radioresistance.
Modulation of notch signalling
A number of studies have investigated the potential of the notch pathway as a novel therapeutic target. 136 The notch 1 receptor and jagged1 ligand both have key roles in the progression and metastasis of prostate cancer and, therefore, represent potential therapeutic targets.
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Downregulated expression of the genes encoding notch 1 or jagged1 has been shown to result in decreased prostate cancer cell invasion. 57, 137, 138 Downregulation of notch 1 and jagged1 with small interfering RNA (siRNA) led to inhibition of cell growth, migration, inva sion, and induction of apoptosis in PC3 prostate cancer cells. 139 In one study, inhibition of notch 1 and jagged1 also led to activation of the AKT pathway, mTOR, and genes downstream of NFκB. 138 In PC3 and C42B cell lines, downregulation of notch 1 with siRNA signifi cantly decreased expression of FOXM1, which is over expressed in prostate cancer cells and has been associated with carcino genesis. 139 This effect seems to be caused by the inactivation of AKT, one of the notch 1 downstream target genes. 139 Although most studies have focused on the downregulation of notch 1, one study established that the retroviral transduction of the active form of notch 1 into DU145 cells led to reduced cell migration and reduced repopulation of wounded monolayers when compared with nontransduced controls. 15 Finally, treat ment with the isoflavone genistein resulted in significant downregulation of notch 1, AKT phosphorylation, and foxM1 expression and inhibition of tumour growth in the PC3 and C42B cell lines. 139 The RBPJ transcriptional repressor is another identi fied target. 140 RBPJ expression was successfully knocked down by lentiviralbased transfer of RBPJspecific small hairpin RNA in the PC3CMVluc prostatederived cell line. This knockdown was associated with decreased cell proliferation, changes in the expression of notch pathway genes, and loss of RBPJ DNA binding activ ity. 46 Modulation by miRNA has also been studied. Transient transfection of vectors expressing miR200 and miR141 decreased the concentration of jagged1 and inhibited cell proliferation in PC3 cells. 73 On the other hand, overexpression of miR34a decreased the expres sion of notch 1, AR, and PSA in LNCaP and C42B pros tate cancer cell lines. 141 Γsecretase inhibitors are the only notch inhibitors currently being evaluated in clini cal trials, with clinical benefit reported in patients with advanced solid tumours 142, 143 and breast cancer. 144 The efficacy of these compounds remains to be assessed in men with prostate cancer.
Conclusions
The notch signalling pathway has been associated with tumorigenesis in a number of cancer types. Current research suggests its involvement in prostate cancer. At the same time, hypoxia is becoming widely accepted as a feature of solid tumours, but evidence of its role in disease progression remains limited, despite the fact that the hypoxic response triggers critical molecular path ways. The notch pathway has been proposed as a thera peutic target for the treatment of prostate cancer, lung cancer, and other hypoxic tumour types. A number of studies have experimented with modulation of the notch signalling pathway in order to develop novel treatments for prostate cancer, yet few have studied the role of notch in the response of cells to hypoxia. Close examination of the interplay between notch and hypoxia signalling pathways has the potential to provide further insight into the regulation and treatment response of the cancer stem cell population while expanding our understanding of angiogenesis in prostate tumours. Further evidence for this potential crosstalk is required in prostate cancer. Future studies should contribute to the identification of a molecular signature for disease progression and treat ment response in prostate cancer and, ultimately, help to identify novel therapeutic targets.
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